Expectant Management of Ectopic Pregnancy
Evaluation of Expectant Management in Women Diagnosed With a Tubal Ectopic Pregnancy at Ain-Shams University Maternity Hospital Over the Period From January 1, 2016 to December 31, 2020
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams University Maternity Hospital
-
Contact:
- Ahmed Essam
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Participants included in this study will have the following criteria:
- Hemodynamically stable with confirmed diagnosis of ectopic pregnancy on ultrasound scan.
- No significant pelvic pain.
- No hemoperitoneum.
- No fetal heart in the ectopic pregnancy.
- HCG level <5000 IU/L.
- Expectant management was the first line of management offered to the patient after optimal counseling.
Description
Inclusion Criteria:
- all women who underwent expectant management as the first line of management offered after optimal counseling during the period from January 1, 2016 to December 31, 2020.
- Hemodynamically stable with confirmed diagnosis of ectopic pregnancy on ultrasound scan.
- No significant pelvic pain.
- No hemoperitoneum.
- No fetal heart in the ectopic pregnancy.
- HCG level <5000 IU/L.
- Expectant management was the first line of management offered to the patient after optimal counseling.
Exclusion Criteria:
- all women with non tubal ectopic pregnancy
- all women with tubal ectopic pregnancy that recieved medical or surgical treatment as 1st line treatment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
resolution of hCG level
Time Frame: up to 12 weeks
|
hCG levels measured every week till negative less than (<20 IU/l) up to 12 weeks
|
up to 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASU FM1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.